Niacinamide, Hyaluronic Acid, Peptides & Bakuchiol

Pregnancy

MotherToBaby describes general factors that affect topical absorption, including amount applied, product form, application site and area, age, wet or dry skin, and skin integrity; its page does not measure these named ingredients. Marie et al.'s 2022 French National College of Midwives guideline recommends reducing the number and frequency of cosmetic products and the amount applied during the perinatal period, and prefers simple, fragrance-free, rinsable products as expert consensus. Draelos et al. (2021) studied one hyaluronic acid serum in 40 women aged 30 to 65 for six weeks and excluded participants who were pregnant, breastfeeding, or planning pregnancy; the study had no placebo group. Navarrete-Solís et al. (2011) tested 4% niacinamide for eight weeks in 27 adult women with melasma and excluded pregnant and nursing women. Park (2022) reviewed seven topical bakuchiol/photoaging reports from 2014 to 2021 and states that clinical studies had not been performed in pregnant people; its positive pregnancy suggestion was mechanism-based. Davis et al. (2026) list niacinamide as a second-line option for melasma and hyaluronic acid for striae, but the pregnancy trial cited for the striae discussion tested a cream containing hydroxyprolisilane-C, rosehip oil, Centella asiatica triterpenes, and vitamin E, not hyaluronic acid. Kovacs et al. (2026) describe high-quality perinatal data and formal guidance for cosmetic dermatology as limited.

Breastfeeding

MotherToBaby describes general skin-uptake factors but gives no milk measurements for topical niacinamide, hyaluronic acid, peptides, or bakuchiol. Draelos et al. and Navarrete-Solís et al. excluded breastfeeding or nursing participants from their adult skin studies. Park's 2022 review says there were no clinical bakuchiol studies in nursing people and frames its suggestion by mechanism rather than infant outcomes. Kovacs et al.'s August 2026 review describes the literature as largely observational reports, case reports, and extrapolation from nonpregnant groups, and distinguishes lactation from pregnancy. DeBoer et al. (2026) analyzed milk vitamin B3 after oral maternal nicotinamide supplementation at 250 mg/day in 1,173 mother-child dyads; this is an oral route, not topical skincare. These sources do not establish topical ingredient-specific milk transfer or infant outcomes.

What was tested

The studies located measured adult skin appearance, hydration, or photoaging, not pregnancy or infant outcomes. Draelos et al. tested one hyaluronic acid facial serum for six weeks in 40 women aged 30 to 65; the article reports a 55% hydration increase from baseline at week six, had no placebo group, excluded pregnant and breastfeeding participants, and was funded by Colgate-Palmolive. Navarrete-Solís et al. randomized 27 adult women with melasma to 4% niacinamide on one side of the face and 4% hydroquinone on the other for eight weeks; pregnant and nursing women were excluded. Park's review included seven topical bakuchiol reports from 2014 to 2021, including adult photoaging work but no clinical studies in pregnant or nursing people. Liu et al. (2026) studied an 88-person, 112-day post-laser regimen combining niacinamide with Pro-Xylane, panthenol, and other ingredients; it did not assess perinatal outcomes and disclosed commercial conflicts. The 2025 hyaluronic acid review concerns skin penetration and cosmetic applications, not systemic or perinatal outcomes. DeBoer et al.'s oral nicotinamide study measured human-milk vitamin B3 after oral supplementation, not topical product transfer.